← Back to Search

Local Anesthetic

Mg and Bupivacaine for Opioid Use Disorder

N/A
Waitlist Available
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients undergoing unilateral primary total knee arthroplasty with spinal anesthetic and MAC followed by a unilateral adductor canal block with ultrasound guidance.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours after surgery
Awards & highlights

Summary

This trial will compare the use of two different drugs to see if one can result in decreased opioid consumption and improved pain management for patients after total knee arthroplasty.

Eligible Conditions
  • Opioid Use Disorder
  • Postoperative Pain

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the second 24 hours after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and the second 24 hours after surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Total opioid consumption (oral morphine equivalents) in the first 24 hours after surgery
Total opioid consumption (oral morphine equivalents) in the second 24 hours after surgery
Visual analog scale (VAS) pain score at 24 hours after surgery
+1 more
Secondary study objectives
Overall patient satisfaction in first 48 hours after surgery
Percentage of incidence of post-operative nausea/ vomiting in first 48 hours after surgery

Trial Design

2Treatment groups
Active Control
Group I: Mg and BupivacaineActive Control1 Intervention
Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 150mg of Mg.
Group II: Buprenorphine and BupivacaineActive Control1 Intervention
Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 300 mcg of buprenorphine.

Find a Location

Who is running the clinical trial?

Wayne State UniversityLead Sponsor
312 Previous Clinical Trials
108,951 Total Patients Enrolled
~26 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top